TMPRSS2 and prostate cancer: The presence of multiple fusion transcript isoforms was most notable in the prostate cancer samples, where 10 out of 11 (91%) TMPRSS2-ERG positive samples expressed two or more alternative isoforms (Supplementary Fig. 9a).